lurbinectedin + irinotecan

**Lurbinectedin + irinotecan** is a combination of two chemotherapeutic agents under clinical investigation for the treatment of small cell lung cancer (SCLC) and other advanced solid tumors. **Lurbinectedin** is a synthetic oncogenic transcription inhibitor that binds to guanine residues in the minor groove of DNA, causing DNA breaks and apoptosis, particularly in transcription-addicted cells. **Irinotecan** is a topoisomerase I inhibitor that causes DNA damage by stabilizing the cleavable complex of topoisomerase I and DNA, leading to cell death. The combination has shown synergistic effects in preclinical and early clinical studies, with promising efficacy (overall response rate exceeding 50% in certain SCLC populations) and a generally manageable safety profile. This regimen is being tested in pivotal phase 3 trials for relapsed SCLC and is also being explored in other advanced solid tumors[1][3][4][5].

Other names

lurbinectedin + irinotecan